Back to discover

Protein / target

C-C motif chemokine 20

Encoded byCCL20P78556Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

CCR6 chemokine receptor binding

Strongest disease association

Inflammatory Bowel Diseases

Via encoding gene CCL20 · Genetic evidence · score 0.75

Research activity

Emerging research

1 papers · latest 1998

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Acts as a ligand for C-C chemokine receptor CCR6.

View complete UniProt function annotation

Acts as a ligand for C-C chemokine receptor CCR6. Signals through binding and activation of CCR6 and induces a strong chemotactic response and mobilization of intracellular calcium ions (PubMed:11035086, PubMed:11352563, PubMed:20068036). The ligand-receptor pair CCL20-CCR6 is responsible for the chemotaxis of dendritic cells (DC), effector/memory T-cells and B-cells and plays an important role at skin and mucosal surfaces under homeostatic and inflammatory conditions, as well as in pathology, including cancer and various autoimmune diseases (PubMed:21376174). CCL20 acts as a chemotactic factor that attracts lymphocytes and, slightly, neutrophils, but not monocytes (PubMed:11352563, PubMed:9038201). Involved in the recruitment of both the pro-inflammatory IL17 producing helper T-cells (Th17) and the regulatory T-cells (Treg) to sites of inflammation. Required for optimal migration of thymic natural regulatory T cells (nTregs) and DN1 early thymocyte progenitor cells (By similarity). C-terminal processed forms have been shown to be equally chemotactically active for leukocytes (PubMed:11035086). Positively regulates sperm motility and chemotaxis via its binding to CCR6 which triggers Ca2+ mobilization in the sperm which is important for its motility (PubMed:23765988, PubMed:25122636). Inhibits proliferation of myeloid progenitors in colony formation assays (PubMed:9129037). May be involved in formation and function of the mucosal lymphoid tissues by attracting lymphocytes and dendritic cells towards epithelial cells (By similarity). Possesses antibacterial activity towards E.coli ATCC 25922 and S.aureus ATCC 29213 (PubMed:12149255)

Subcellular location

Secreted
Domains and Gene Ontology detail (15)

Gene Ontology

  • Cextracellular region
  • Cextracellular space
  • FCCR6 chemokine receptor binding
  • Fchemokine activity
  • Pcalcium-mediated signaling
  • Pcell chemotaxis
  • Pcell-cell signaling
  • Pchemotaxis
  • Pdefense response to bacterium
  • Pimmune response
  • Pinflammatory response
  • Ppositive regulation of T cell migration

96 aa · 11 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationUniProt · GOImmune signallingUniProt · GO
View supporting evidence

Cell migration

  • ·Acts as a ligand for C-C chemokine receptor CCR6. Signals through binding and activation…
  • ·cell chemotaxis
  • ·chemotaxis
  • ·positive regulation of T cell migration

Immune signalling

  • ·Acts as a ligand for C-C chemokine receptor CCR6. Signals through binding and activation…
  • ·immune response
  • ·inflammatory response
  • ·positive regulation of T cell migration

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CCL20

Gene-level evidence surfaced through the gene CCL20that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Inflammatory Bowel Diseases
0.78Well supported

Genetic evidence dominant · Open Targets 0.48

Colitis, Ulcerative
0.71Moderately supported

Genetic evidence dominant · Open Targets 0.42

Hypersensitivity
0.69Moderately supported

Genetic evidence dominant · Open Targets 0.42

Hypothyroidism
0.68Moderately supported

Genetic evidence dominant · Open Targets 0.42

Crohn's Disease
0.68Moderately supported

Genetic evidence dominant · Open Targets 0.41

View evidence synthesis (5)
Inflammatory Bowel DiseasesWell supported
0.78
agreement 0.660.91
Genetic86%Literature13%RNA expression1%

Open Targets aggregate 0.48 · 3 independent evidence families

Colitis, UlcerativeModerately supported
0.71
agreement 0.590.84
Genetic79%Literature12%RNA expression9%

Open Targets aggregate 0.42 · 3 independent evidence families

HypersensitivityModerately supported
0.69
agreement 0.550.83
Genetic90%Literature10%

Open Targets aggregate 0.42 · 2 independent evidence families

HypothyroidismModerately supported
0.68
agreement 0.560.80
Genetic100%

Open Targets aggregate 0.42 · 1 independent evidence family

Crohn's DiseaseModerately supported
0.68
agreement 0.550.81
Genetic85%Literature13%RNA expression2%

Open Targets aggregate 0.41 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Inflammatory Bowel Diseases0.48
Colitis, Ulcerative0.42
Hypersensitivity0.42
Hypothyroidism0.42
Crohn's Disease0.41
Childhood onset asthma0.40
Rhinitis, Allergic0.35
Asthma0.32
Psoriasis0.31
Respiratory Tract Diseases0.31

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
SM · Structure with LigandAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 1998

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.